[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2013102431A1
公开(公告)日:2013-07-11
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
提供了用于治疗癌症的化合物以及治疗癌症的方法,包括向需要的受试者施用本文所述的化合物。
Thiazolidinones, their production and use as pharmaceutical agents
申请人:Schulze Volker
公开号:US20060223833A1
公开(公告)日:2006-10-05
The invention relates to thiazolidinones of general formula (I)
their production and use as inhibitors of polo-like kinases (Plk) for treating various diseases.
本发明涉及通式(I)的噻唑啉酮及其生产和用作极化样激酶(Plk)抑制剂治疗各种疾病。
Novel 2-pyridinecarboxamide derivatives
申请人:Mitsuya Morihiro
公开号:US20060258701A1
公开(公告)日:2006-11-16
The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I):
[wherein X
1
represents a nitrogen atom, sulfur atom, oxygen atom or the like; R
1
represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R
3
are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II)
represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III)
represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I):
[wherein X
1
represents a nitrogen atom, sulfur atom, oxygen atom or the like; R
1
represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R
2
and R
3
are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II)
represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III)
represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.